Altimmune, Inc. is a late clinical-stage biopharmaceutical company developing novel therapies for serious liver diseases. Its lead product candidate, pemvidutide (formerly ALT-801), is a balanced 1:1 glucagon/GLP-1 dual receptor agonist in clinical development for metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). As of December 31, 2025, over 700 patients have been exposed to pemvidutide across 8 completed and 2 ongoing clinical studies.
Q2 FY2026 — expected 2026-09-19
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-06 | 2025-12-31 | 0001326190-26-000018 | EDGAR | 79K words |
| 2025-02-27 | 2024-12-31 | 0001326190-25-000015 | EDGAR | — |
| 2024-03-27 | 2023-12-31 | 0001326190-24-000010 | EDGAR | — |
| 2023-02-28 | 2022-12-31 | 0001326190-23-000008 | EDGAR | — |
| 2022-03-15 | 2021-12-31 | 0001558370-22-003659 | EDGAR | — |
| 2021-02-25 | 2020-12-31 | 0001564590-21-008422 | EDGAR | — |
| 2020-03-27 | 2019-12-31 | 0001564590-20-013377 | EDGAR | — |
| 2019-04-01 | 2018-12-31 | 0001564590-19-010429 | EDGAR | — |
| 2018-04-02 | 2017-12-31 | 0001193125-18-103623 | EDGAR | — |
| 2017-03-14 | 2016-12-31 | 0001144204-17-014528 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-06 | 2025-09-30 | 0001326190-25-000064 | EDGAR | 16K words |
| 2025-08-12 | 2025-06-30 | 0001326190-25-000040 | EDGAR | — |
| 2025-05-13 | 2025-03-31 | 0001326190-25-000034 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0001326190-24-000050 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0001326190-24-000030 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0001326190-24-000019 | EDGAR | — |
| 2023-11-07 | 2023-09-30 | 0001326190-23-000047 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0001326190-23-000036 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0001326190-23-000028 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0001326190-22-000013 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0001558370-22-013271 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0001558370-22-008535 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-07-28 | 0001326190-26-000044 | EDGAR | — |
| 2026-03-05 | 0001326190-26-000013 | EDGAR | 3K words |
| 2026-02-03 | 0001326190-26-000008 | EDGAR | — |
| 2026-01-28 | 0001326190-26-000006 | EDGAR | — |
| 2025-12-19 | 0001104659-25-122724 | EDGAR | — |
| 2025-12-01 | 0001104659-25-117144 | EDGAR | — |
| 2025-11-06 | 0001326190-25-000067 | EDGAR | — |
| 2025-11-06 | 0001326190-25-000055 | EDGAR | — |
| 2025-10-03 | 0001326190-25-000053 | EDGAR | — |
| 2025-09-25 | 0001326190-25-000050 | EDGAR | — |
319 total filings indexed. 287 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001326190 |
| Ticker | ALT |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.altimmune.com |
| Listed | 2005-10-06 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/ALT (~200 tokens, structured JSON with cryptographic provenance)